🇺🇸 SR-fampridine in United States
29 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 29
Most-reported reactions
- Fall — 8 reports (27.59%)
- Anaemia — 4 reports (13.79%)
- Condition Aggravated — 3 reports (10.34%)
- Angina Unstable — 2 reports (6.9%)
- Constipation — 2 reports (6.9%)
- Drug Dose Omission — 2 reports (6.9%)
- Loss Of Consciousness — 2 reports (6.9%)
- Malaise — 2 reports (6.9%)
- Multiple Sclerosis — 2 reports (6.9%)
- Muscle Spasticity — 2 reports (6.9%)
Other Neurology approved in United States
Frequently asked questions
Is SR-fampridine approved in United States?
SR-fampridine does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for SR-fampridine in United States?
University of Southern Denmark is the originator. The local marketing authorisation holder may differ — check the official source linked above.